Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
Launched by ALLERGAN · Mar 9, 2020
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with refractory glaucomas, including cases where previous surgical treatment has failed, cases of POAG, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy
- Exclusion Criteria:
- • Angle closure glaucoma where angle has not been surgically opened
- • Previous glaucoma shunt/valve in the target quadrant
- • Presence of conjunctival scarring, prior conjunctival surgery or other conjunctival pathologies (eg, pterygium) in the target quadrant
- • Active inflammation (eg, blepharitis, conjunctivitis, keratitis, uveitis)
- • Active iris neovascularization or neovascularization of the iris within six months of the surgical date
- • Anterior chamber intraocular lens
- • Presence of intraocular silicone oil
- • Vitreous present in the anterior chamber
About Allergan
Allergan, a global leader in pharmaceutical innovation, specializes in developing and commercializing a diverse portfolio of advanced therapeutic and aesthetic products. With a commitment to improving the health and well-being of patients, Allergan conducts rigorous clinical trials to evaluate the safety and efficacy of its therapies across various medical fields, including ophthalmology, dermatology, and neuroscience. The company is dedicated to adhering to the highest ethical standards and regulatory guidelines, ensuring that its research not only advances medical science but also meets the needs of healthcare providers and patients worldwide. Through strategic collaborations and a focus on scientific excellence, Allergan continues to drive advancements in treatment options and enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Qionghai, Hainan, China
Patients applied
Trial Officials
ALLERGAN INC.
Study Director
Allergan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials